(PharmaNewsWire.Com, April 23, 2018 ) Respiratory Inhaler market is anticipated to grow at XX% CAGR from 2017 to 2022 and it is estimated that the global market was valued at USD XX billion in 2017 and is expected to reach USD 4.41 billion by 2022.
Respiratory inhaler devices are medical instruments that are used to diagnose people with patient suffering from breathing problems arising from respiratory disorders such as COPD, fibrosis, asthma, and ARDS and others.
The rising prevalence of COPD, asthma, chronic respiratory diseases, and other respiratory diseases are anticipated to boost the growth of the Global respiratory inhaler market. With the growing trend of combined therapies among patients due to associated benefits such as more reliable in complex patients, increased efficacy coupled with favorable reimbursement policies associated with therapy is further expected to aid the market growth. Be that as it may, factors such as a dire shortage of skilled pulmonologist, physicians and nurses coupled with lack of awareness among patients in developing nations, absence of a single effective inhaler devices for a variety of disease indication, side effects and complications during drug inhalation, coupled with high prices of inhaler devices are factors restraining market growth.
The global Respiratory Inhaler market is segmented on the basis of Product, Technology and Disease Indication. On the basis of Product, the market is segmented into Dry Powder Inhaler, Metered Dose Inhaler, and Nebulizer. The Nebulizer segment is further sub-segmented into Compressed Air Nebulizers, Ultrasonic Nebulizers, and Mesh Nebulizers. On the basis of Technology, the market is segmented into Manually Operated Inhaler Devices, and Digitally Operated Inhaler Devices. On the basis of Disease Indication, the market is segmented into Asthma, COPD, Pulmonary Arterial Hypertension, and Others Respiratory Disease.
On the basis of geography, the Respiratory Inhaler market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. As of 2017, North America is estimated to account for the major share of the overall respiratory inhaler devices market. Asia Pacific is expected to witness the highest growth rate in the coming years.
The market is dominated by companies like AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding and Teva Pharmaceutical Industries Ltd.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: